Drug Profile


Alternative Names: Aflibercept/REGN 2176; Eylea/REGN-2176; Eylea/rinucumab; PDGFR-beta-Eylea combination therapy - Bayer/Regeneron; REGN-2176-3; REGN-2176/aflibercept; REGN-2176/Eylea; Rinucumab/aflibercept; Rinucumab/Eylea

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Regeneron Pharmaceuticals
  • Class Antibodies; Eye disorder therapies; Monoclonal antibodies; Recombinant fusion proteins
  • Mechanism of Action Placenta growth factor inhibitors; Platelet-derived growth factor beta receptor antagonists; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Wet age-related macular degeneration

Most Recent Events

  • 30 Sep 2016 Top-line efficacy and safety data from a phase II trial in Wet age-related macular degeneration released by Regeneron Pharmaceuticals
  • 11 Feb 2016 Aflibercept/rinucumab receives Fast Track designation for Wet age-related macular degeneration [Intravitreous,Injection] (In the elderly, In adults) in USA
  • 01 Apr 2015 Phase-II clinical trials in Wet age-related macular degeneration (In the elderly, In adults) in Japan and USA (Intravitreous) (NCT02418754)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top